• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New classification of drug induced liver injury (DILI) in AASLD guidance: What is next?

作者信息

Ercin Cemal Nuri

机构信息

Department of Gastroenterology, Health Sciences University, Gulhane School of Medicine, Ankara, Turkiye.

出版信息

Hepatol Forum. 2024 Mar 8;5(2):61-62. doi: 10.14744/hf.2024.2024.0011. eCollection 2024.

DOI:10.14744/hf.2024.2024.0011
PMID:38487735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10936121/
Abstract
摘要

相似文献

1
New classification of drug induced liver injury (DILI) in AASLD guidance: What is next?美国肝病研究学会（AASLD）指南中药物性肝损伤（DILI）的新分类：接下来是什么？
Hepatol Forum. 2024 Mar 8;5(2):61-62. doi: 10.14744/hf.2024.2024.0011. eCollection 2024.
2
AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury: also useful for hepatobiliary surgeons.美国肝病研究学会关于药物、草药和膳食补充剂所致肝损伤的实践指南：对肝胆外科医生也有用。
Hepatobiliary Surg Nutr. 2023 Oct 1;12(5):746-751. doi: 10.21037/hbsn-23-319. Epub 2023 Sep 13.
3
The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury.肝脏毒性知识库 (LKTB) 和药物性肝损伤 (DILI) 分类用于评估人类肝损伤。
Expert Rev Gastroenterol Hepatol. 2018 Jan;12(1):31-38. doi: 10.1080/17474124.2018.1383154. Epub 2017 Oct 9.
4
Drug-induced liver injury: recent advances in diagnosis and risk assessment.药物性肝损伤：诊断与风险评估的最新进展
Gut. 2017 Jun;66(6):1154-1164. doi: 10.1136/gutjnl-2016-313369. Epub 2017 Mar 23.
5
[Significance of histological assessment in drug-induced liver injury].[组织学评估在药物性肝损伤中的意义]
Zhonghua Gan Zang Bing Za Zhi. 2023 Apr 20;31(4):349-354. doi: 10.3760/cma.j.cn501113-20230421-00184.
6
Idiosyncratic drug-induced liver injury: an overview.特异质性药物性肝损伤：概述
Expert Opin Drug Saf. 2007 Nov;6(6):673-84. doi: 10.1517/14740338.6.6.673.
7
Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity.药物性肝损伤严重程度和毒性（DILIst）：1279 种药物的人类肝毒性的二进制分类。
Drug Discov Today. 2020 Jan;25(1):201-208. doi: 10.1016/j.drudis.2019.09.022. Epub 2019 Nov 1.
8
Utility of a Computerized ICD-10 Algorithm to Identify Idiosyncratic Drug-Induced Liver Injury Cases in the Electronic Medical Record.计算机化 ICD-10 算法在电子病历中识别特发性药物性肝损伤病例的效用。
Drug Saf. 2020 Apr;43(4):371-377. doi: 10.1007/s40264-019-00903-5.
9
The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury.药物性肝损伤的免疫机制及基于免疫的生物标志物
Front Pharmacol. 2021 Oct 15;12:723940. doi: 10.3389/fphar.2021.723940. eCollection 2021.
10
A proposed pathologic sub-classification of drug-induced liver injury.药物性肝损伤的病理亚型分类建议。
Hepatol Int. 2019 May;13(3):339-351. doi: 10.1007/s12072-019-09940-9. Epub 2019 Apr 11.

引用本文的文献

1
Morin: a promising hepatoprotective agent against drug and chemical-induced liver injury.桑色素：一种有望用于对抗药物和化学物质诱导肝损伤的肝保护剂。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 26. doi: 10.1007/s00210-025-04394-3.

本文引用的文献

1
Drug induced liver injury - a 2023 update.药物性肝损伤——2023年最新进展
J Toxicol Environ Health B Crit Rev. 2023 Nov 17;26(8):442-467. doi: 10.1080/10937404.2023.2261848. Epub 2023 Oct 19.
2
An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation.药物性肝损伤机制的免疫学观点：以治疗肝细胞癌和肝移植的药物为重点。
Int J Mol Sci. 2023 Mar 5;24(5):5002. doi: 10.3390/ijms24055002.
3
Checkpoint inhibitor hepatotoxicity: pathogenesis and management.检查点抑制剂肝毒性：发病机制与管理
Hepatology. 2024 Jan 1;79(1):198-212. doi: 10.1097/HEP.0000000000000045. Epub 2023 Jan 13.
4
Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach.检查点抑制剂诱导的肝毒性：肝活检的作用及管理方法
World J Hepatol. 2022 Jul 27;14(7):1269-1276. doi: 10.4254/wjh.v14.i7.1269.
5
AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.美国肝病研究学会关于药物、草药和膳食补充剂所致肝损伤的实践指南。
Hepatology. 2023 Mar 1;77(3):1036-1065. doi: 10.1002/hep.32689. Epub 2023 Feb 17.
6
Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management.药物性肝损伤：发病机制、流行病学、临床特征及实用管理。
Eur J Intern Med. 2022 Mar;97:26-31. doi: 10.1016/j.ejim.2021.10.035. Epub 2021 Nov 9.
7
Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation.药物性肝损伤的生物标志物：在研究、医学和监管中的进展和应用。
Expert Rev Mol Diagn. 2018 Sep;18(9):797-807. doi: 10.1080/14737159.2018.1508998. Epub 2018 Aug 13.
8
Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis.药物性肝损伤：导致细胞死亡、凋亡或坏死的一系列事件
Int J Mol Sci. 2017 May 9;18(5):1018. doi: 10.3390/ijms18051018.
9
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.与免疫抑制及生物调节剂治疗相关的乙型肝炎再激活：当前概念、管理策略及未来方向
Gastroenterology. 2017 May;152(6):1297-1309. doi: 10.1053/j.gastro.2017.02.009. Epub 2017 Feb 20.
10
Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.药物性肝损伤：机制理解方面的进展将为风险管理提供依据。
Clin Pharmacol Ther. 2017 Apr;101(4):469-480. doi: 10.1002/cpt.564. Epub 2017 Jan 11.